Detalhe da pesquisa
1.
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML.
Leukemia
; 36(3): 701-711, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34750506
2.
Inhibition of wild-type and mutant Bcr-Abl by pyrido-pyrimidine-type small molecule kinase inhibitors.
Cancer Res
; 63(19): 6395-404, 2003 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14559829
3.
Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.
Clin Cancer Res
; 19(11): 2962-72, 2013 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23549879
4.
FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
Cancer Res
; 69(7): 3032-41, 2009 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19318574
5.
Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).
Blood
; 108(4): 1328-33, 2006 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-16614241
6.
A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.
Blood
; 105(4): 1652-9, 2005 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15459011